RLYB
Rallybio Corporation NASDAQ$14.12
Mkt Cap $74.7M
52w Low $2.16
96.1% of range
52w High $14.60
50d MA $8.66
200d MA $5.83
P/E (TTM)
-5.9x
EV/EBITDA
0.0x
P/B
0.9x
Debt/Equity
0.0x
ROE
-15.5%
P/FCF
-1.0x
RSI (14)
—
ATR (14)
—
Beta
-1.20
50d MA
$8.66
200d MA
$5.83
Avg Volume
146.7K
About
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody which is in Phase II clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the p…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | AMC | -1.24 | -1.28 | -3.2% | 9.60 | -0.2% | -1.0% | -2.0% | +0.5% | -2.5% | -5.3% | — |
| Nov 6, 2025 | AMC | -0.25 | -0.14 | +44.0% | 5.11 | -2.9% | -2.2% | +1.8% | +10.4% | +9.4% | +2.7% | — |
| Aug 7, 2025 | AMC | -0.20 | -0.22 | -12.8% | 4.09 | +1.2% | +3.9% | -2.7% | -1.5% | +4.6% | +6.8% | — |
| May 8, 2025 | AMC | -0.21 | -0.21 | +0.0% | 2.34 | +0.0% | +0.0% | +3.0% | +1.7% | +6.0% | +9.4% | — |
| Mar 13, 2025 | AMC | -0.27 | -0.25 | +7.4% | 5.25 | -2.1% | -3.6% | -2.1% | +12.0% | +11.0% | +6.7% | — |
| Nov 7, 2024 | AMC | -0.36 | -0.26 | +27.8% | 7.92 | +0.0% | +1.0% | +6.1% | +12.1% | +10.1% | +2.0% | — |
| Aug 8, 2024 | AMC | -0.42 | -0.37 | +11.9% | 9.52 | +3.4% | -4.2% | -7.6% | -4.2% | -8.4% | -6.7% | — |
| May 9, 2024 | AMC | -0.50 | -0.47 | +6.0% | 15.20 | +2.1% | -3.7% | -6.3% | -3.2% | +0.5% | -2.1% | — |
| Mar 12, 2024 | AMC | -0.44 | -0.50 | -13.6% | 13.44 | +1.8% | +4.8% | -4.8% | -3.6% | -3.0% | -4.8% | — |
| Nov 9, 2023 | AMC | -0.51 | -0.45 | +11.8% | 24.32 | -0.3% | -5.6% | -16.4% | -21.4% | -23.2% | -34.7% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 15 | Jones Trading | Downgrade | Buy → Hold | — | $2.16 | $2.10 | -2.8% | -2.8% | -6.9% | -7.4% | -1.9% | +5.1% |
| Apr 9 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $2.00 | $1.80 | -10.0% | +0.0% | +0.0% | +0.0% | +8.0% | +5.0% |
| Mar 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.06 | $5.08 | +0.4% | +1.6% | +16.2% | +15.2% | +10.7% | +5.9% |
| Feb 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.97 | $5.84 | -2.2% | -2.8% | +5.2% | +1.0% | -1.5% | +3.0% |
| Jan 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.52 | $7.52 | +0.0% | -1.9% | -5.3% | -4.3% | -5.3% | -6.9% |
| Dec 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.04 | $9.12 | +0.9% | -6.2% | -3.5% | -6.2% | -6.2% | +2.7% |
| Nov 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.91 | $8.00 | +1.1% | +3.2% | +6.2% | +9.2% | +11.3% | +18.3% |
| Nov 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.92 | $7.92 | +0.0% | +1.0% | +6.1% | +12.1% | +10.1% | +2.0% |
| Oct 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.16 | $8.08 | -1.0% | +0.0% | +1.0% | -1.0% | +0.0% | +0.0% |
| Oct 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.36 | $9.36 | +0.0% | -4.3% | -6.8% | -6.0% | -5.1% | -3.4% |
Recent Filings
8-K · 1.02
!! High
Rallybio Corporation -- 8-K 1.02: Material Agreement Terminated
I cannot determine the specific reason for termination (breach, mutual, regulatory, or expiration) from the information provided, so I'm unable to write the requested sentence accurately without speculating.
May 4
S-4
!!! Very High
Rallybio Corporation -- Merger Registration
Rallybio Corporation shareholders will receive a name change to Candid Therapeutics, Inc. upon completion of a merger transaction.
Apr 24
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
An executive departure at Rallybio signals potential leadership instability and warrant expiration within 90 days post-merger, which could pressure stock price and dilute shareholder value.
Mar 31
S-4
!!! Very High
Unknown — Merger Registration
Rallybio is merging with an unknown entity, likely resulting in significant changes to ownership structure and stock terms that existing shareholders must evaluate for dilution and value implications.
Mar 17
8-K
Rallybio Corporation -- 8-K Filing
Rallybio's merger with Candid will convert Candid option holders' shares into Rallybio options, with final ownership percentages dependent on Rallybio's cash position at closing.
Mar 2
Data updated apr 26, 2026 11:03pm
· Source: massive.com